(Q43564478)

English

Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder

scientific article published in January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 November 2017

Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder (English)

1 reference

Europe PubMed Central

24 November 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

B Olsson

1

1 reference

Europe PubMed Central

24 November 2017

J Szamosi

2

1 reference

Europe PubMed Central

24 November 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

24 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

24 November 2017

40

1 reference

Europe PubMed Central

24 November 2017

2

1 reference

Europe PubMed Central

24 November 2017

135-143

1 reference

Europe PubMed Central

24 November 2017

https://scigraph.springernature.com/pub.10.2165/00003088-200140020-00005

0 references

Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Food increases the bioavailability of tolterodine but not effective exposure

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interactions affecting drug absorption

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The overactive bladder: an overview for primary care health providers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of first-pass hepatic clearance of propranolol by food

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individual variation in first-pass metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The patient with an overactive bladder--symptoms and quality-of-life issues

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum protein binding of tolterodine and its major metabolites in humans and several animal species

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11286323

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003088-200140020-00005

1 reference

Europe PubMed Central

24 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43564478&oldid=2143698868"